الفهرس 
coverOnly 14 pages are availabe for public view
 |  | from | 107 |  |  |
| | | from | 107 | | |
Abstract
Classically, common therapies for thromboprophylaxis among pregnant females are heparin (either unfractionated and or low molecular weight heparin), vitamin K antagonists and antiplatelets. Recently, newer agents have been introduced into practice including danaporoids, direct thrombin inhibitors and fondaparinux. It should be noted that choice of antithrombotic agent during pregnancy is primarily based upon efficacy of antithrombotic agent to reduce maternal morbidity and mortality risks for associated condition with pregnancy and at the same time possess no or minimal inadvertent fetal and maternal complication. Unfractionated heparin has been used for decades for many indications during pregnancy. It is a large molecule, so it does not cross the placenta and thus, in contrast to the coumarin derivatives, does not cause teratogenesis or toxic fetal effects. Over the last 10 years LMWHs have become the preferred anticoagulants for treating and preventing thromboembolism in all patients. While comparative data are much less robust in pregnant patients, several series have confirmed the safety and efficacy of LMWHs in pregnancy